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Background: There are different treatment options, but little support of evidence in the 
treatment of patients with resistant schizophrenia. In this study we used antipsychotic 
polypharmacy (AP) comprising 1200 mg of amisulpride and 600 mg of quetiapine, 
using neurocognitive evaluations to measure clinical change. 
 
Study Question: The AP of amisulpride and quetiapine implicará una mejoría clínica 
en pacientes with resistant schizophrenia que reflejará especialmente en una mejoría 
cognitiva. 
 
Study Design: Naturalistic and prospective study. 26 patients with no biological 
response to medication, high social maladjustment, a long history of the disease, to 
whom Kane's and Brenner's criteria for treatment-resistant schizophrenia were applied 
and assessed by a battery of neurocognitive evaluations desde a pre-treatment baseline y 
a los six months treatment. 
 
Measures and Outcomes: La mejoría cognitiva implicara una mejora significativa in 
the cognitive test: Stroop test, WAIS Coding Subtest, Continuous Trail Making Test 
(CTMT) desde la línea base y los 6 meses de tratamiento. También implicará mejoría en 
las escalas de Calgary Depression Scale (CDS), Simpson-Angus Scale (SAS) and a 
Visual Analogue Scale (EVA) con las que fueron evaluados en línea base, a los 3 meses 
y a los 6 meses. 
 
Results: Subjects, after six months treatment with amisulpride and quetiapine, did 
statistically significant difference in the assessed areas: WAIS Coding Subtest (P 
<0.001), CTMT A & B (CTMTA P< 0,034; CTMTB P< 0,000) and in Stroop tests: 
Word (P< 0,001), word-color (P< 0,007) and interference (P< 0,039). Furthermore they 
showed a statistically significant difference in CDS (P< 0,002), SAS (P< 0,019), and 
EVA (P < 0.001). 
 
Conclusion: The results of this report show a cognitive and clinical improvement in 
refractory patients after the administration of amisulpride and quetiapine. 
 





Refractoriness in Schizophrenia 
Refractory treatment, resistance to treatment and lack of response to treatment are all 
used to define schizophrenic patients whose symptoms are not improved by 
antipsychotic medication. The generally accepted criteria for defining treatment 
resistance in schizophrenia were initially used by Kane. 1 Brenner 2 subsequently 
defined treatment resistance in schizophrenia in a less restrictive manner. Refractoriness 
is not presented as a dichotomic quality, but as a continuum. 
 
Table 1. Criteria of Kane et al. 1  for Resistant Schizophrenia 
Treatment with 2 antipsychotic drugs from different chemical classes, at doses equivalent to 
1000 mg/d of chlorpromazine, for at least 3 periods of 6 weeks in the previous 5 years, without 
significant clinical improvement. 
Reduction of less than 20% in score on the BPRS, posttreatment BPRS score more than 35 
points, CGI score more than 3, after treatment with 60 mg/d of haloperidol for 6 weeks. 
Total score on the BPRS more than 45. Score more than 2 on the BPRS items of conceptual 
disorganization, unusual thoughts, hallucinatory behavior, and suspiciousness. Score on the 
CGI scale more than 4. 









Table 2. Criteria of Brenner et al. 2 of Continuum of Response-Resistance to Treatment in 
Schizophrenia 
Level 1 Clinical remission Rapid and substantial response to antipsychotics at recommended doses. The 
patient may present anhedonia or other negative symptoms. CGI, normal. Score 
less than 2 on all the items of the BPRS. Good functional level without 
supervision. 
Level 2 Partial remission Rapid reduction of psychotic symptoms. Slight signs of residual psychotic 
symptoms. CGI, 2. None of the BPRS items score 3 or more. 
Level 3 Mild resistance Slow and incomplete reduction of the symptoms, with residual positive and 
negative symptoms. Alteration of personal and social functioning in 2 or more 
areas that require occasional supervision. CGI, 3. No more than 1 item with a score 
of 4 or more on the BPRS. 
Level 4 Moderate resistance There is a reduction of symptoms, but a clear persistence of symptoms affecting 4 
or more areas of personal and social functioning that require frequent supervision. 
CGI, 4. A score of 4 on 2 BPRS items. A total BPRS score of at least 45 in the 18-
item version and of 60 in the 24-item version. 
Level 5 Severe resistance There is a reduction of symptoms, but a clear persistence of symptoms affecting 6 
or more areas of personal and social functioning that require frequent supervision. 
CGI, 5. A score of 5 on 1 BPRS item or at least of 4 on 3 items. A total BPRS 
score of at least 50 in the 18-item version and of 67 in the 24-item version. 
Level 6 Refractoriness Slight or nonobjectifiable reduction of symptoms and persistence of positive and 
negative symptoms that lead to a marked alteration in all areas of personal and 
social functioning. CGI, 6. A score of 6 in 1 BPRS item or at least of 5 in 2 items. 
Total BPRS score at least as for level 5. 
Level 7 Severe refractoriness No reduction of symptoms, with a large quantity of positive and negative 
symptoms associated with behavior disorders. All areas of personal and social 
functioning show severe deterioration and require constant supervision. CGI, 7. A 
score of 7 in 1 BPRS item. Total BPRS score at least as for level 5. 
Abbreviations: CGI Clinical Global Impression; BPRS Brief Psychiatric Rating Scale. 
 
Apparent resistance to treatment may not only be due to pharmacological problems, as 
it could be related to other factors. According to some authors, apparent resistance to 
treatment could be related to therapeutic non-compliance 3 especially in cases involving 
drug abuse. Some studies estimate that 30% of patients are refractory to 
pharmacological treatment 4 and present a younger age of onset than responders. 5 
According to clinical trials, only 20% of schizophrenic patients present complete 
remission with appropriate antipsychotic treatment and 20% to 30% of this group suffer 
a relapse during the first year of treatment. 6-7 
 
Cognitive deficits in Schizophrenia 
 
It was in the last decade of last century when the study of cognitive decline associated 
with this illness began with emphasis. 8 There is considerable literature concerning 
cognitive deficits associated to schizophrenia, but there is little information about the 
cognitive aspects of refractory schizophrenia. Although this deficits are varied, it has 
been found that the most consistent and relevant in the disease’s evolution are sustained  
alterations affecting attention, verbal and work memory, long-term memory, executive 
functions, categorization, cognitive flexibility and verbal fluency. 9-12 Even so, there is a 
clear need to more precisely delimit altered and preserved cognitive processes, and how 
these alterations are related to types of symptom, 13 the disease’s evolution, 14 or even 
medication. 15,16 
 
With respect to cognitive aspects of refractory schizophrenia, the information published 
in the scientific literature is very scarce. Two research projects were conducted based on 
the criteria established by Kane et al 1 with contradictory results. The study published by 
Joober et al 17 evaluated attention and vigilance, abstraction and flexibility, spatial 
organization, visual motor processing, visual memory, verbal intelligence and language, 
and visual memory and learning. It was found that refractory patients perform worse in 
all areas in comparison with non-refractory patients, primarily in visual memory, verbal 
intelligence and language and significantly only in visual memory and learning. On the 
other hand, in a study conducted in the Álava Psychiatric Hospital 18 it is shown that the 
neurocognition of these patients does not differ from that of people with chronic 
schizophrenia. The different results can be explained by the differences in the 
responding patient samples. Whereas Joober’s study included patients with 6-8 weeks 
of good response to treatment, with total or partial stabilization of symptoms and with 
no need to be hospitalized, the Álava study included hospitalized patients with recurring 
symptoms or who had been admitted for the severity of their global psychopathology.19 
 
Pharmacological treatment in resistant patients 
 
Current pharmacological treatment options for subjects not responding to antipsychotic 
therapy are very limited. In treatment resistant patients, clozapine has been shown to be 
the “Gold Standard”, nevertheless, clozapine had serious potential side effects, such as 
neutropenia and agranulocytosis, weight gain, diabetes and cardiomiopathy. 20-22 It’s 
also estimated that a high percentage, between 47% and 63% of these patients treated 
with clozapine, continue without an appropriate response. 23 The use of antipsychotic 
polypharmacy (AP) could be of interest in this context. Various descriptive studies have 
found that AP was used before clozapine, 24 and some authors' investigations 
recommend a combination of clozapine with other antipsychotic agents 25 or the 
combined use of other antipsychotic agents, including amisulpride. 26-28 On the other 
hand there are studies with amisulpride in schizophrenia which show a good safety 
profile of the drug and a significant improvement in Positive and Negative Syndrome 
Scale (PANSS) 29 eight weeks after treatment and keeping it for twelve months. 30 
 
Precisely, according to certain authors, amisulpride presents a similar cognitive 
improvement to atypical antipsychotics, as olanzapine, but with better performance in 
attention and executive function and worse, although not significantly so, in work 
memory. 31 Other investigators conclude that amisulpride presents a significantly greater 
effect than typical first generation antipsychotic agents, and is at least as effective as 
olanzapine and risperidone. 26 They also found that amisulpride produced a greater 
improvement in both the positive and negative symptoms of schizophrenia, a better 
long-term result than typical antipsychotic agents and different tolerance advantages. 
Furthermore, they also believe that adjuvant treatment of clozapine therapy is useful in 
patients with refractory schizophrenia, proposing an AP combination of 
amisulpride/clozapine for these patients. 32 
 
In recent years, the use of amisulpride as a combined strategy for refractory 
schizophrenia has woken the interest up of both investigators and clinicians, proposing 
for these patients an AP combination of amisulpride/clozapine 32-34 or 
amisulpride/olanzapine. 35 However, the combination of amisulpride/quetiapine might 
also be useful. There is evidence of a significant improvement in PANSS and Calgary 
Depression Scale for Schizophrenia (CDS) 36 with a combination therapy of 
amisulpride/quetiapine in patients with insufficient responses to quetiapine 
monotherapy. 37 
 
From the pharmacodynamic perspective, quetiapine show less than 60% D2 occupancy 
with minimal extrapyramidal side effects and minimal effects on prolactin levels due to 
a fast decline in D2 occupancy. 38 Clinical consequence is the need to add an agent to 
reach an optimal occupancy of D2 receptors. There are also studies that suggest a good 
efficacy and tolerance of quetiapine in treatment resistant schizophrenia. 39 A rationale 
strategy for this can be to add amisulpride, an antipsychotic with a high affinity for D2 
receptor blockade. On the contrary, olanzapine and risperidone, with intermediate K-off, 
can increase D2 receptor blockade on monotherapy increasing dosage. In addition, 
amisulpride has a preference on the limbic system and the hypothalamus, increasing the 
cortical dopaminergic transmission and inhibiting the limbic, and has low or no affinity 
for muscarinic, histaminic and adrenergic receptors. Amisulpride’s metabolism is nearly 
absent, being largely unchanged at urine and faecal excretion. We propose that this 
combination is appropriate for its use as a rational strategy given their 
pharmacodynamic and pharmacokinetic profile and their advantages in the cognitive 
areas. In this report, we describe the cognitive and therapeutic effects of combined 
treatment with amisulpride and quetiapine in a sample of 26 patients with refractory 
schizophrenia. 
 
Materials and method 
This is a naturalistic, observational, prospective study of a non randomized sample of 
treatment resistant schizophrenic patients. The protocol was approved by the clinical 
ethics review committee at the study site. All patients signed written informed consent 




Sample of recruited patients was, at first, 26 but only 19 (73.07% from total) finished 
treatment by protocol with all complete information. Left rate was 19.23%. The mean 
age (n=26) was 37.65 years (DE=1.67). Mean time to the diagnosis of schizophrenia 
was 15.1 years (SD, 11.1 years), and the mean number of hospital admissions since the 
diagnosis was 5.8 (SD 4.6).  Descriptive of patients for the sample are presented Table 
3. 
 
Most participants were men (76.9%), lived with a family member (76.9%), retired from 
work (42.3%), and were of a fairly low socioeconomic status (50%). Demographic 
characteristics for the sample are presented in table 4. Most participants (84.6%) denied 




Table 3.  Descriptive of patients. 
 N Minimum Maximum Means Stand. desv 
Time evolution 26 0 44 15.12 11.15 
Admissions number 21 0 15 5.86 4.68 
Age 26 20 65 37.65 11.67 
 
Table 4.  Socio-demographic characteristics of the sample. 
 Frequency Percentage 
Studies level Primary school 7 26.9 
Secondary school 9 34.6 
Vocational training course 2 7.7 
Technician 3 11.5 
Degree 5 19.2 
Total 26 100 
Coexistence Alone 3 11.5 
Family 20 76.9 
Institutionalised 2 7.7 
Others 1 3.8 
Total 26 100 
Occupation Employed 5 19.2 
Unemployed 3 11.5 
TIW* 1 3.8 
Pensioner 11 42.3 
Non- contributory state pension 6 23.1 




Low 3 11.5 
Medium low 13 50.0 
Medium 8 30.8 
Medium high 2 7.7 
Total 26 100 
Sex Male 20 76.9 
Female 6 23.1 
Total 26 100 
Note: TIW*= Temporary Incapacity for Work 
 
All the subjects met DSM-IV-TR 40 diagnostic criteria for schizophrenia. They were all 
interned and presented a long history of recurrence and lack of sufficient response to 
treatment. They also met the criteria for treatment-resistant schizophrenia established by 
Kane et al 1 and Brenner et al. 2 
 
The fact that the patients were non-responders and their long history of recurrence and 
continued internment justified the use of AP. They were administered such therapy 
comprising 1200 mg of amisulpride and 600 mg of quetiapine. 
 
Assessment 
They were subjected to cognitive evaluations comprising a pre-treatment baseline 
assessment and a evaluation at six months. The primary study endpoint were defined as 
mean changes in cognitive test: On the Stroop, 41 Coding (WAIS) 42 neurocognitive 
scales and performance time in Comprehensive Trail making test (CTMT) 43-44 scores at 
six months from baseline. 
 
It was also applied Calgary Depression Scale test 36 taking as baseline two and three 
months treatment and the end at six months treatment; Visual Analogue Scale (EVA) 45 
in baseline assesment and at three and six months treatment; Simpson-Angus Scale 
(SAS) 46 at two and three months treatment and in the end at six months treatment. 
 
Results 
Data were analysed with the statistic support SPSS v.15. using ANOVA for repeated 
measures with a 95% confidence interval for analysis calculating in each visit and in 
medium change (effect size) the months after baseline assessment. 
 
As it can be seen in table 5, subjects including in this report showed a global 
improvement in performance on all the scales. These differences are significant in every 























Table 5.  Descriptive of tests. 
    Confidence interval 
of 95% 




EVA LB. 5.31 .41 4.45 6.18 
 3 m. 7.37 .33 6.66 8.07 
 6 m. 7.63 .24 7.12 8.14 
SAS 2 m. 2.22 .52 1.14 3.31 
 3 m. 1.36 .31 .71 2.01 
 6 m. 1.22 .28 .65 1.80 
CDS LB 8.18 1.25 5.58 10.78 
 2 m. 6.41 1.20 3.91 8.90 
 3 m. 4.13 .91 2.24 6.03 
 6 m. 3.00 .84 1.25 4.74 
STROOP  
Color 
LB 46.00 4.20 36.92 55.08 
6 m. 51.43 5.60 39.32 63.54 
STROOP 
Word 
LB 62.71 7.07 47.44 77.99 
6 m. 71.50 8.40 53.34 89.66 
 STROOP 
Word-Color 
LB 30.57 1.87 26.53 34.61 
6 m. 36.43 2.84 30.30 42.56 
STROOP 
Interference 
LB 4.22 2.32 -0.78 9.23 
6 m. 23.57 6.76 8.96 38.17 
CTMT A LB 80.16 8.46 62.31 98.01 
6 m. 70.50 8.97 51.56 89.44 
CTMT B LB 149.78 22.87 101.51 198.04 
6 m. 118.72 22.11 72.06 165.38 
Coding LB 49.50 4.76 39.46 59.54 
 6 m. 61.00 5.71 48.94 73.06 
Abbreviations: EVA= Visual analogue scale. SAS= Simpson-Angus Scale. CDS= Calgary Depression 











Tabla 6. Analysis of variance (ANOVA) for repeated measures. 
 Confidence interval 
















EVA LB 3 m. -2.05(*) .41 .000 -3.15 -.95 
 LB 6 m. -2.31(*) .52 .001 -3.70 -.93 
 3m 6 m. -.26 .39 1.000 -1.29 .76 
SAS 2 m. 3 m. .86(*) .32 .039 .04 1.69 
 2m 6 m. 1.00(*) .33 .019 .14 1.85 
 3m 6 m. .13 .15 1.000 -.25 .53 
CDS LB 2 m. 1.77 1.17 .878 -1.65 5.19 
 LB 3 m. 4.04(*) 1.11 .009 .802 7.29 
 LB 6 m. 5.18(*) 1.18 .002 1.7 8.61 
 2m 3 m. 2.27(*) .72 .028 .18 4.36 
 2m 6 m. 3.41(*) .85 .004 .91 5.19 
 3m 6 m. 1.13 .39 .051 -.002 2.27 
Stroop Color LB 6 m. -5.43 2.88 .083 -11.66 .80 
Stroop Word LB 6 m. -8.78(*) 2.18 .001 -13.50 -4.07 
Stroop Word-Color LB 6 m. -5.85(*) 1.84 .007 -9.83 -1.88 
Stroop  Interference LB 6 m. -19.34(*) 8.41 .039 -37.51 -1.18 
CTMT A LB 6 m. 9.66(*) 4.19 .034 .82 18.51 
CTMT B LB 6 m. 31.05(*) 7.21 .000 15.83 46.28 
Coding LB 6 m. -11.50(*) 2.90 .001 -17.63 -5.37 
Notes: Score based on the estimated marginal means: (*) The significant difference of the mean is to the 
level, 05. (a) Adjustment for multiple comparisons: Bonferroni. 
Abbreviations: EVA= Visual analogue scale. SAS= Simpson-Angus Scale. CDS= Calgary Depression 
Scale. Stroop= Color and Word Test. CTMT= Comprehensive Trail Making Test. Coding = WAIS 
Coding Subtest. 
 
The scores of Coding Subtest WAIS went from a mean baseline 49.5 to a mean of 61 
after six months of treatment. This difference between means was statistically 
significant (P < 0.001). 
 
Patients showed an improvement in the execution of CTMT (Test A & B) (CTMTA 
mean baseline 80.1 to mean 70.5 and CTMTB mean baseline 149.7 to 118.7). These 
differences in means were statistically significant for both CTMTA (P< 0.034) and 
CTMTB (P< 0.000). 
 
There was an improvement in Word (mean baseline 62.7 to 71.5; P< 0.001), Color-
Word (mean baseline 30.5 to 36.4; P< 0.007) and Interference (mean baseline 4.2 to 
23.5; P< 0.039) Stroop tests. It had been shown a non-significant increase in the Color 
Stroop test (mean baseline 46 to 51.4; P<0.083). 
 
In addition to the neuropsychological scales, patients showed an improvement in CDS 
scores from a mean of 8.1 in baseline to 6.4 two months later; to 4.1 at three months and 
3 at the end of treatment. The scores’ difference between baseline and six months 
treatment was significant (P< 0.002). 
 
SAS mean baseline was 2.2 two months after treatment, 1.3 at three months and 1.2 at 
six months. The scores between mean baseline and six months were significant 
(P<0.019). 
 
EVA scores increased from 5.3 at baseline to 7.3 at three months and 7.6 at six months. 
The scores between mean baseline and six months were significant (P< 0.019). 
In this same study other authors 47 found that AP application of amilsulpride and 
quetiapine produced a significant better change in the scores on the clinical scales six 
months after treatment: PANSS: 29 Mean PANSS scores for positive symptoms 
decreased from 21.1  to 11.7 at 6 months;  Negative symptom scores was from 26.9 to 
15.8  at 6 months; General psychopathology state PANSS, decreased from 50.8  to 28.6 
at 6 months. Differences between means in PANSS scores were statistically significant 
(P<0.000), Brief Psychiatric Rating Scale (BPRS): 48 mean general baseline 29.6 to 14 
at 6 months (P< 0.000) and Clinical Global Impression Severity of Illness (CGI-S) 49 
mean baseline 5.4 to 3.4 at 6 months (P< 0.000). 
 
Discussion 
SAS scores during the treatment, showing a low rate of extrapyramidal side effects. 
These results are consistent with those obtained by authors such as Pani et al 26 showing 
that one of the advantages of amisulpride compared with other antipsychotic agents was 
tolerance, particularly in relation to extrapyramidal symptoms. 
 
The combination therapy of amisulpride and quetiapine for managing treatmentresistant 
schizophrenia has shown to improve symptoms, function and quality of life. 47 Research 
into the cognitive aspects of schizophrenia is currently very important. 8 We have used a 
wide battery of neurocognitive tests in our patients, focusing to those measuring 
executive functions. The presence of neurocognitive measurements to show 
improvement in schizophrenic patients is justified by several aspects. Many 
investigators suggest that these dysfunctions are significant and central to the disease, 50 
while others believe that cognitive functions form and integral part of the treatment 
resistance concept. 51 This cognitive deficit is presented irrespective of positive and 
negative symptoms, even when the association with these symptoms is greater. 52 
Logically, the degree of cognitive deficit is related to poorer adjustment in patients’ 
quality of life. 53 Its importance made it suggested as a new diagnostic criteria for 
schizophrenia in the DSM-5 classifications. 54-55 
 
With regards to the effect of medication on neurocognitive symptoms, it appears that 
second generation antipsychotic agents can improve these deficits. Olanzapine produces 
greater cognitive improvement than risperidone and haloperidol. 56-57 With a dose of 
olanzapine 20 mg/day, risperidone 6 mg/day or haloperidol 20 mg/day (1 year of 
flexible follow-up, adapting dosage to patient status), it was found that the domains 
most benefiting after 6 months of treatment with olanzapine versus risperidone and 
haloperidol were memory, attention, visual motor speed, executive function, verbal 
fluency and psychomotor speed. 58 Continuing with second generation neuroleptic 
agents, investigations showed that quetiapine is superior to haloperidol in improving 
cognitive function. 59 In this study, patients who received 600 mg per day of quetiapine 
improved their scores in verbal fluency, the Stroop Color-Word Test and in 
remembering paragraphs versus those receiving haloperidol. The overall improvement 
was at least as good as with olanzapine but better in some areas. 
 
On the Stroop and Coding (WAIS) neurocognitive scales, the subjects including in our 
study performed better and obtained higher scores than pre-treatment. In this sense, 
Velligan et al 59 found also that patients receiving 600 mg per day of quetiapine 
presented improved verbal fluency and Stroop Color-Word Test results. In the CTMT 
results, performance time was better. 
 
Improvement results CDS for Schizophrenia are consistent with those found by 
Englisch 37 in his AP study of quetiapine and amisulpride in schizophrenic patients with 
insufficient responses to quetiapine monotherapy in which, after 8.3 weeks of treatment, 
they found a significant improvement of Calgary Depression Scale for Schizophrenia. 
 
Conclusion 
The results of this report do show cognitive improvement in refractory patients after the 
administration of amisulpride and quetiapine. Note that these patients were affected by 
considerable social maladjustment, lack of biological response to medication, long-term 
disease, unemployment or internment, low educational level, low socio-cultural level 
and insufficient clinical response in the past 
 





A limitation of this study is the sample size as well as the allocation procedure 
followed. As a result, findings are supported by observations derived from a small 
number of participants who were recruited into the study on a convenience base. 
However, the main purpose of the study was to show the cognitive and clinical benefits 
that can be obtained from using amisulpride plus quetiapine in treatment resistant 
schizophrenia patients addressing issues related to their efficacy and security profile for 
controlling cognitive and clinical symptoms of disease. It reflects regular clinical 
practice for individuals with psychiatric disorders in the Spanish healthcare setting and 
opens up a line for conducting further research into the value of these therapeutic 
alternatives in poor responders to other treatment schemes. 
 
Several authors refer to the need for naturalistic or real-life studies designed to shed 
light on the antipsychotics that should be preferred in usual clinical practice to treat 
chronic schizophrenia and poor responders to treatments. 60,61 Similar to other research 
findings 62,63 in this study, differences in clinical and patient-centered outcomes had 
been most significant over the first 3 months of treatment while stabilizing toward the 
sixth month. However, the main purpose of the study was to describe the clinical and 
cognitive improvements that can be obtained from using amisulpride plus quetiapine in 
patients with treatment resistant schizophrenia. It opens up a line for conducting further 
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